Author: yourbiotech
Emerging biopharma has gradually taken over the R&D pipeline, producing two-thirds of all new drugs in 2022, a finding one financial biotech player called “stunning.” “Emerging biopharma has been rising at roughly 4% a year for each of the last five years,” Tim Opler, Ph.D., managing director for life sciences investment bank Torreya, said during a March 29 presentation of IQVIA’s report on global R&D trends. Opler, citing the IQVIA data, dubbed the stat an “absolutely stunning finding.” “Go back to, say, the year 2005,” Opler said. “If someone told you that two-thirds of our industry would be driven on the R&D side by emerging biopharma—it…
s the health impacts of climate change become harder to ignore, biotechnology and pharmaceutical companies are facing increasing pressure from investors, employees, and government regulators to reduce their carbon emissions, and to make environmental sustainability a core part of their business. Globally, large public biotech and pharmaceutical companies are responsible for more than 200 million metric tons of carbon dioxide and equivalent emissions, according to estimates from one 2022 report. The bulk of those emissions are tied to companies’ products and supply chains, which can be hard to measure. In the U.S., about 8.5% of the national carbon footprint can be…
the court heard arguments in a dispute over rights to therapeutic antibodies that are used to treat high cholesterol in people at risk of cardiovascular disease. Although the court’s justices spent much of their time wrestling with the details of how these antibodies are isolated, their decision — expected by the end of June — could affect how specific patents of any ilk must be when they describe an invention, and how broad they can be. “It could spill over into all types of biotechnology cases,” says Sean Tu, a legal scholar at West Virginia University in Morgantown. “Today we’re…
On a windy, overcast day in November last year, 27 biotech CEOs, led by the head of Biotech Australia, Lorraine Chiroiu, arrived in Canberra for their annual meeting with the minister for industry and science and a day of presentations from a shuffle of bureaucrats. This year’s gathering was especially significant – there was a new Labor minister, Ed Husic, and both the government and Biotech Australia had just published strategy documents for the future of the industry in this country. Perhaps most importantly, the COVID-19 pandemic had indirectly, and unexpectedly, led to a 40 percent increase in the number…
After a decade in the pharmaceutical industry where she had a hand in developing prominent drugs including the immunosuppressive drug Humira, Shao-Lee Lin started her own biopharma company. She founded Acelyrin in 2020, armed with $8 million in Series A funding. It was one of 165 Series A funding rounds in the space that year. In 2021, Lin said Acelyrin had the potential to become “the next Amgen,” a pharma company that has been around since the ’80s. “We really are after building a long-term sustainable biopharma company that ultimately has fully integrated R&D as well as commercialization,” Lin told me when I was…
In this piece, we will take a look at the 12 best biotechnology stocks to buy under $20. For more stocks, head on over to 5 Best Biotech Stocks To Buy Under $20. The biotechnology industry is one of the hottest sectors right now, particularly in the aftermath of the coronavirus pandemic since it was this industry that developed messenger ribonucleic acid (mRNA) vaccines that put an end to the pandemic. However, biotechnology does not only target viruses in its drug development efforts. While mRNA might have been popularized due to the coronavirus pandemic, the technology which programs the human…
When you think of life sciences and biotech hubs in the U.S., where do you travel to in your mind? Boston? The Bay Area? Texas? Portal Innovations, a biotech VC firm based in Chicago, is trying to broaden everyone’s horizons and give opportunities to biotech startups growing out of labs in Chicago, Atlanta, and hopefully beyond. “I founded Portal Innovations really to address emerging needs for life sciences companies, particularly in ecosystems, like Chicago, that don’t yet have the infrastructure and community to support a growing life sciences community emerging from our research institutions,” Portal’s CEO, John Flavin, explains. Over…
$100 million for Rapport Therapeutics. $112 million for Noema Pharma. $108 million for Bicara Therapeutics. The mega-round has come roaring back in the past few weeks, but is biotech really healing? Not quite, say executives from venture capital and biotech incubator firms. Series A rounds are an easy sell at the moment, according to Leaps By Bayer Head Jürgen Eckhardt, M.D., although fewer of them overall are getting done and the ones that are, are smaller. What’s continuing to hamper biotech is the series Bs, Cs, and crossover rounds that set up an IPO. That’s where Flagship Pioneering Senior Partner…
For Sangamo Therapeutics, last week is probably one to forget. Late Friday, the gene-based therapy biotech revealed it had lost two partners in quick succession, with Biogen and Novartis walking away from partnerships collectively worth billions of dollars in milestones within days of each other. Novartis was the first to break up with Sangamo. One week ago, the Swiss Big Pharma told Sangamo of its plans to terminate the agreement the companies entered into in 2020. Back then, Novartis paid $75 million upfront and committed up to $720 million in milestones to apply Sangamo’s zinc finger protein transcription factors (ZFP-TFs) to three…
The Golden Ticket will help to boost the biotech startup’s capabilities and to develop further the emerging biotech ecosystem in Southeast Asia SINGAPORE, March 20, 2023 /PRNewswire/ — Leading global biotechnology company Amgen and NSG BioLabs, Singapore’s largest and leading provider of biotechnology (biotech) co-working laboratories and offices, announced Albatroz Therapeutics as the winner of the first Amgen Golden Ticket in Singapore. Albatroz Therapeutics will be rewarded a one-year free residency in NSG Biolabs’ fully-equipped, turnkey, and certified BSL-2 laboratory, as well as additional facility benefits and connections to Amgen’s scientific and business leaders. (PRNewsfoto/NSG BioLabs) The Amgen Golden Ticket winner was chosen by an internal team of Amgen scientific…
